Waters: From AAVs to Emerging Vectors: See What CDMS Reveals
Discover solutions for characterizing today's AAVs and tomorrow's viral vectors
CDMS in Action: Driving Better AAV Processes and Deeper Viral Vector Insights
Thursday, November 5
10:00 AM EST
Join Lexeo Therapeutics and Waters to learn how CDMS accelerates AAV process development and expands characterization of emerging viral vectors.
Overview
In this webinar, experts from Lexeo Therapeutics and Waters show how charge detection mass spectrometry (CDMS) resolves AAV capsid populations that other methods can miss. Discover how these insights accelerate process development, quality decisions, and characterization of emerging viral vectors, including lentivirus, adenovirus, and virus-like particles (VLPs). Register now to see CDMS in action for your next gene therapy program.
Topics you'll explore:
- Gain deeper insight into AAV vector quality by resolving empty, partial, full, and higher-order capsid populations
- Learn how CDMS drives real-world AAV process optimization across manufacturing, purification, and scale-up
- Discover how CDMS expands to characterize emerging viral vectors, including adenovirus, lentivirus, and VLPs
If you are unable to attend the session, you can still register to receive a link to watch the webinar on-demand after its initial broadcast.
Explore Our Upcoming Events
Be part of the conversations that matter. Whether you’re looking to learn, connect, or get inspired, our upcoming events offer something for everyone.